ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (4): 15-21.doi: 10.6040/j.issn.1673-3770.0.2016.278
李勇
LI Yong
中图分类号:
| [1] Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy [J]. J Allergy Clin Immunol, 2015, 136(3): 556-568. [2] Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper [J]. Allergy, 2014, 69(7): 854-867. [3] 中国过敏性鼻炎研究协作组. 过敏性鼻炎皮下免疫治疗专家共识2015 [J]. 中国耳鼻咽喉头颈外科, 2015, 22(8): 379-404. [4] Calderon M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions [J]. Allergy, 2012, 67(4): 462-476. [5] CMS update: desensitizing vaccines [J]. Br Med J, 1986, 293(6552): 984. [6] 宋薇薇, 林小平, 柴若楠, 等. 东北地区夏秋季花粉症患者变应原特异性免疫治疗的长期疗效 [J]. 中华临床免疫和变态反应杂志, 2012, 6(4): 266-271. SONG Weiwei, LIN Xiaoping, CHAI Ruonan, et al. Long-term efficacy of allergen specific immunotherapy for pollinosis patients in northeast china [J]. Chin J Allergy Clin Immunol, 2012, 6(4): 266-271. [7] 关凯, 魏庆宇, 尹佳. 葎草花粉变应原免疫治疗疗效和安全性评估 [J]. 中华临床免疫和变态反应杂志, 2012, 6(4): 279-284. GUAN Kai, WEI Qingyu, YIN Jia. Efficacy and safety of specific immunotherapy with Humulus Pollen extract[J]. Chin J Allergy Clin Immunol, 2012, 6(4): 279-284. [8] 叶世泰, 李美琏, 何海娟, 等. 过敏性鼻炎患者在特异性脱敏治疗中血清IgE的动态观察 [J]. 中华耳鼻咽喉科杂志, 1982, 17(2): 147-148. [9] 文昭明,叶世泰. 免疫疗法致不良反应的临床观察——附29例报告[J]. 中华微生物学和免疫学杂志, 2001(S2):68-71. [10] 张罗, 韩德民. 变应性鼻炎的变应原特异性皮下免疫治疗 [J]. 中华耳鼻咽喉头颈外科杂志, 2007, 42(9): 711-716. ZHANG Luo, HAN Demin. Allergen-specific subcutaneous immunotherapy for allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2007, 42(9):711-716. [11] 尹佳. 北京协和医院变应原制剂应用指南 [M]. 北京: 中国协和医科大学出版社, 2014. [12] Canonica G W, Baena-Cagnani C E, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization(WAO)taskforce [J]. Allergy, 2007, 62(3): 317-324. [13] Rosner-Friese K, Kaul S, Vieths S, et al. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs [J]. J Allergy Clin Immunol, 2015, 135(3): 636-643. [14] Brozek J L, Bousquet J, Baena-Cagnani C E, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010,126(3):466-476. [15] Canonica G W, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update[J]. World Allergy Organ J, 2014,7(1):6. [16] Wilson D R, Lima M T, Durham S R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis[J]. Allergy, 2005,60(1):4-12. [17] Pitsios C, Demoly P, Bilò M B, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper [J]. Allergy, 2015, 70(8): 897-909. [18] Casale T B, Stokes J R. Immunotherapy: what lies beyond [J]. J Allergy Clin Immunol, 2014, 133(3): 612-619: quiz 620. [19] von Moos S, Johansen P, Tay F, et al. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy [J]. J Allergy Clin Immunol, 2014, 134(4): 965-967.e964. [20] Tabar A I, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus[J]. J Allergy Clin Immunol, 2005, 116(1): 109-118. [21] Temino V M, Wu P, Konig J, et al. Safety of multiple aeroallergen rush immunotherapy using a modified schedule [J]. Allergy Asthma Proc, 2013, 34(3): 255-260. [22] Rieker-Schwienbacher J, Nell M J, Diamant Z, et al. Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients [J]. Clin Transl Allergy, 2013, 3(1): 16. [23] Durham S R, Walker S M, Varga E M, et al. Long-term clinical efficacy of grass-pollen immunotherapy [J]. N Engl J Med, 1999, 341(7): 468-475. [24] Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation, Allergy, 1996, 51(6): 430-433. [25] Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study [J]. J Allergy Clin Immunol, 2010, 126(5): 969-975. [26] Calderon M A, Cox L, Casale T B, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence [J]. J Allergy Clin Immunol, 2012, 129(4): 929-934. [27] Calderon M A, Cox L S. Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: a debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas [J]. J Allergy Clin Immunol Pract, 2014, 2(2): 136-143. [28] Nelson H S. Multiallergen immunotherapy for allergic rhinitis and asthma [J]. J Allergy Clin Immunol, 2009, 123(4): 763-769. [29] Amar S M, Harbeck R J, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract [J]. J Allergy Clin Immunol, 2009, 124(1): 150-156.e151-155. [30] Canonica G W, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009 [J]. Allergy, 2009, 64(Suppl 91): 1-59. [31] Kim J M, Lin S Y, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review [J]. Pediatrics, 2013, 131(6):1155-1167. [32] Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update [J]. J Allergy Clin Immunol, 2011, 127(Suppl 1): S1-55. [33] Cox L S, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review [J]. J Allergy Clin Immunol, 2006, 117(5): 1021-1035. [34] Makatsori M, Scadding G W, Lombardo C, et al. Dropouts in sublingual allergen immunotherapy trials-a systematic review [J]. Allergy, 2014, 69(5): 571-580. [35] Passalacqua G, Baena-Cagnani C E, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language [J]. J Allergy Clin Immunol, 2013, 132(1): 93-98. [36] Cox L, Larenas-Linnemann D, Lockey R F, et al. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System [J]. J Allergy Clin Immunol, 2010, 125(3): 569-574, 574.e561-574.e567. [37] Coop C A, Tankersley M S. Patient perceptions regarding local reactions from allergen immunotherapy injections [J]. Ann Allergy Asthma Immunol, 2008, 101(1): 96-100. [38] Kelso J M. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction [J]. Ann Allergy Asthma Immunol, 2004, 92(2): 225-227. [39] Tankersley M S, Butler K K, Butler W K, et al. Local reactions during allergen immunotherapy do not require dose adjustment [J]. J Allergy Clin Immunol, 2000, 106(5): 840-843. [40] Roy S R, Sigmon J R, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy [J]. Ann Allergy Asthma Immunol, 2007, 99(1): 82-86. [41] Epstein T G, Liss G M, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions [J]. J Allergy Clin Immunol Pract, 2014, 2(2): 161-167. [42] Bernstein D I, Epstein T, Murphy-Berendts K, et al. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study [J]. Ann Allergy Asthma Immunol, 2010, 104(6): 530-535. [43] Tinkelman D G, Cole W Q, 3rd Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions [J]. J Allergy Clin Immunol, 1995, 95(1 Pt 1): 8-14. [44] Cox L, Aaronson D, Casale T B, et al. Allergy immunotherapy safety: location matters [J]. J Allergy Clin Immunol Pract, 2013, 1(5): 455-457. [45] Calderon M A, Simons F E, Malling H J, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile [J]. Allergy, 2012, 67(3): 302-311. [46] de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet [J]. Allergy, 2009, 64(6): 963-964. [47] Miehlke S, Alpan O, Schroder S, et al. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy [J]. Case Rep Gastroenterol, 2013, 7(3): 363-368. [48] HollisterStier Allergy, Allergenic extracts in bulk vial. Available at: http://www.hsallergy.com/products_ordering/product_inserts.aspx. In, May 11, 2013. |
| [1] | 王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74. |
| [2] | 卢汉桂,林歆胜,姚丹勉,魏永新,李创伟. 变应性鼻炎大鼠IL-35的表达及对辅助性T细胞免疫调节的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 66-70. |
| [3] | 浦洪波,杜晓东. 无锡地区2 000例变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 105-107. |
| [4] | 陈鸣,俞雪飞. 浅谈伴有变应性鼻炎的慢性鼻窦炎的治疗[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 18-22. |
| [5] | 覃纲,梁灼萍. 变应性真菌性鼻-鼻窦炎免疫治疗现状[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 23-26. |
| [6] | 吴湘萍. 患者管理方式对变应性鼻炎舌下含服粉尘螨滴剂疗效的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 68-72. |
| [7] | 王岩,师晓丽. 变态反应与儿童OSAHS的关系[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 14-18. |
| [8] | 李松,王宗贵,杨景朴,张竹萍. 鼻内镜下翼管神经切断术进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 72-76. |
| [9] | 郅莉莉,宋道亮. 嗜酸性粒细胞及IL5在上颌窦后鼻孔息肉与鼻息肉中表达的差异[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 43-46. |
| [10] | 万文锦,王文,程雷. 尘螨变应性鼻炎皮下免疫治疗与舌下免疫治疗的荟萃分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 103-108. |
| [11] | 朱新华. 变应性鼻炎冲击免疫治疗的临床应用[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 13-17. |
| [12] | 刘怀涛,马瑞霞,程雷. 难治性变应性鼻炎的外科治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 18-21. |
| [13] | 关凯,李丽莎. 鼻腔冲洗在变应性鼻炎防治中的应用[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 22-27. |
| [14] | 史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12. |
| [15] | 刘静. 基于整体观念变应性鼻炎的中医辨证论治[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 28-30. |
|
||